



## Author Index (Vol. 103)

**Araki, A., Sako, Y. and Ito, H.**

Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus — effect of parenteral methylcobalamin treatment (103) 149

**Atger, V., Leclerc, T., Cambillau, M., Guillemain, R., Marti, C., Moatti, N. and Girard, A.**

Elevated high density lipoprotein concentrations in heart transplant recipients are related to impaired plasma cholesterol ester transfer and hepatic lipase activity (103) 29

**Bais, R., see Roach, P.D. (103) 245****Baraga, J.J., see Manoharan, R. (103) 181****Becker, A.E., see van der Wal, A.C. (103) 55****Berglund, B., see Hellénius, M.-L. (103) 81****Blonk, C.G., see de Deckere, E.A.M. (103) 291****Boissonneault, G.A., see Ramasamy, S. (103) 279****Bors, W., see Hense, H.W. (103) 21****Braun, M., Hohlfeld, T., Kienbaum, P., Weber, A.-A., Sarbia, M. and Schröder, K.**

Antiatherosclerotic effects of oral cicaprost in experimental hypercholesterolemia in rabbits (103) 93

**Bruckdorfer, K.R., see Plane, F. (103) 73****Buikema, H., see Kroon, A.A. (103) 221****Bulleid, S., see MBewu, A.D. (103) 65****Cambillau, M., see Atger, V. (103) 29****Campisi, D., Cutolo, M., Carruba, G., Lo Casto, M., Comito, L., Granata, O.M., Valentino, B., King, R.J.B. and Castagnetta, L.**

Evidence for soluble and nuclear site I binding of estrogens in human aorta (103) 267

**Cardoso-Saldana, G., see Lerman-Garber, I. (103) 195****Carruba, G., see Campisi, D. (103) 267****Castagnetta, L., see Campisi, D. (103) 267****Cierniewski, C.S., see Pawlowska, Z. (103) 13****Clifton, P.M., see Roach, P.D. (103) 245****Comito, L., see Campisi, D. (103) 267****Coyle, P., see Roach, P.D. (103) 245****Cutolo, M., see Campisi, D. (103) 267****Das, P.K., see van der Wal, A.C. (103) 55****Dasari, R.R., see Manoharan, R. (103) 181****De Caterina, R., see Schmidt, E.B. (103) 107****de Deckere, E.A.M., de Fouw, N.J., Ritskes-Hoitinga, J., van Nielen, W.G.L. and Blonk, C.G.**

Effect of an atherogenic diet on lipoprotein cholesterol profile in the F<sub>1</sub>B hybrid hamster (103) 291

**de Faire, U., see Hellénius, M.-L. (103) 81****de Fouw, N.J., see de Deckere, E.A.M. (103) 291****de Wilde, P.C.M., see Kroon, A.A. (103) 221****Dean, R.T., see Sullivan, D.R. (103) 139****Demacker, P.N.M., see Kroon, A.A. (103) 221****Durrington, P.N., see MBewu, A.D. (103) 65****Ehnholm, C., see Salomaa, V. (103) 1****Evans, G.F., see Zuckerman, S.H. (103) 43****Feher, M.D., Webb, J.C., Patel, D.D., Lant, A.F., Mayne, P.D., Knight, B.L. and Soutar, A.K.**

Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolemia (103) 171

**Feld, M.S., see Manoharan, R. (103) 181****Fitzmaurice, M., see Manoharan, R. (103) 181****Frostegård, J., Wu, R., Haegerstrand, A., Patarroyo, M., Lefvert, A.-K. and Nilsson, J.**

Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules (103) 213

**Girard, A., see Atger, V. (103) 29****Granata, O.M., see Campisi, D. (103) 267****Guillemain, R., see Atger, V. (103) 29****Gullberg, B., see Lindberg, G. (103) 123****Haegerstrand, A., see Frostegård, J. (103) 213****Halliday, D., see Pacy, P.J.H. (103) 231****Hamsten, A., see Hellénius, M.-L. (103) 81****Hanson, B.S., see Lindberg, G. (103) 123****Hellénius, M.-L., de Faire, U., Berglund, B., Hamsten, A. and Krakau, I.**

Diet and exercise are equally effective in reducing risk for cardiovascular disease. Results of a randomized controlled study in men with slightly to moderately raised cardiovascular risk factors (103) 81

**Hennig, B., see Ramasamy, S. (103) 279****Hense, H.W., Stender, M., Bors, W. and Keil, U.**

Lack of an association between serum vitamin E and myocardial infarction in a population with high vitamin E levels (103) 21

**Hensley, W.J., see Sullivan, D.R. (103) 139****Hietaniemi, K.L., see Mattila, K.J. (103) 205****Hohlfeld, T., see Braun, M. (103) 93****Hosking, J., see Roach, P.D. (103) 245**

Illingworth, D.R., see Schmidt, E.B. (103) 107  
 Ito, H., see Araki, A. (103) 149

Jacobs, M., see Plane, F. (103) 73  
 Jauhainen, M., see Salomaa, V. (103) 1  
 Jessup, W., see Sullivan, D.R. (103) 139

Kario, K. and Matsuo, T.  
 Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis (103) 131

Keil, U., see Hense, H.W. (103) 21

Kienbaum, P., see Braun, M. (103) 93

King, R.J.B., see Campisi, D. (103) 267

Knight, B.L., see Feher, M.D. (103) 171

Kochhar, A., see Stirk, C.M. (103) 159

Korhonen, H., see Salomaa, V. (103) 1

Krakau, I., see Hellénius, M.-L. (103) 81

Kristensen, S.D., see Schmidt, E.B. (103) 107

Kroon, A.A., Stalenhoef, A.F.H., Buikema, H., Demacker, P.N.M., de Wilde, P.C.M., Leijten, P.A. and van Gilst, W.H.  
 The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits (103) 221

Krzeslowska, J., see Pawlowska, Z. (103) 13

Kusenic, B., see Roach, P.D. (103) 245

Kuulasmaa, K., see Salomaa, V. (103) 1

Lam, C.W.K., see Sullivan, D.R. (103) 139

Lant, A.F., see Feher, M.D. (103) 171

Leclerc, T., see Atger, V. (103) 29

Lefvert, A.-K., see Frostegård, J. (103) 213

Leijten, P.A., see Kroon, A.A. (103) 221

Lerman-Garber, I., Sepúlveda-Amor, J.A., Tapia-Conyer, R., Magos-López, C., Cardoso-Saldana, G., Zamora-González, J., Salvatierra-Izaba, B. and Posadas-Romero, C.  
 Cholesterol levels and prevalence of hypercholesterolemia in Mexican children and teenagers (103) 195

Lindberg, G., Råstam, L., Gullberg, B., Lundblad, A., Nilsson-Ehle, P. and Hanson, B.S.  
 Serum concentrations of total sialic acid and sialoglycoproteins in relation to coronary heart disease risk markers (103) 123

Lipke, D.W., see Ramasamy, S. (103) 279

Lo Casto, M., see Campisi, D. (103) 267

Lundblad, A., see Lindberg, G. (103) 123

Mackness, M.I., see MBewu, A.D. (103) 65  
 Magos-López, C., see Lerman-Garber, I. (103) 195  
 Manoharan, R., Baraga, J.J., Rava, R.P., Dasari, R.R., Fitzmaurice, M. and Feld, M.S.  
 Biochemical analysis and mapping of atherosclerotic human artery using FT-IR microspectroscopy (103) 181

Marti, C., see Atger, V. (103) 29

Matsuo, T., see Kario, K. (103) 131

Mattila, K.J., Valle, M.S., Nieminen, M.S., Valtonen, V.V. and Hietaniemi, K.L.  
 Dental infections and coronary atherosclerosis (103) 205

Mayne, P.D., see Feher, M.D. (103) 171  
 MBewu, A.D., Durrington, P.N., Bulleid, S. and Mackness, M.I.  
 The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein (103) 65

McManus, D., see Plane, F. (103) 73

Mitropoulos, K.A., see Pacy, P.J.H. (103) 231

Moatti, N., see Atger, V. (103) 29

Nestel, P.J., see Roach, P.D. (103) 245

Nicolosi, R.J., see Stucchi, A.F. (103) 255

Nieminen, M.S., see Mattila, K.J. (103) 205

Nilsson, J., see Frostegård, J. (103) 213

Nilsson-Ehle, P., see Lindberg, G. (103) 123

O'Neal, L., see Zuckerman, S.H. (103) 43

Pacy, P.J.H., Mitropoulos, K.A., Venkatesan, S., Watts, G.F., Reeves, B.E.A. and Halliday, D.  
 Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase (103) 231

Patarroyo, M., see Frostegård, J. (103) 213

Patel, D.D., see Feher, M.D. (103) 171

Pawlak, L., see Pawlowska, Z. (103) 13

Pawlowska, Z., Swiatkowska, M., Krzeslowska, J., Pawlak, L. and Cierniewski, C.S.  
 Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia (103) 13

Pekkanen, J., see Salomaa, V. (103) 1

Pietinen, P., see Salomaa, V. (103) 1

Plane, F., Jacobs, M., McManus, D. and Bruckdorfer, K.R.  
 Probucol and other antioxidants prevent the inhibition of endothelium-dependent relaxation by low-density lipoproteins (103) 73

Posadas-Romero, C., see Lerman-Garber, I. (103) 195

Ramasamy, S., Boissonneault, G.A., Lipke, D.W. and Hennig, B.  
 Proteoglycans and endothelial barrier function: effect of linoleic acid exposure to porcine pulmonary artery endothelial cells (103) 279

Rasi, V., see Salomaa, V. (103) 1

Råstam, L., see Lindberg, G. (103) 123

Rava, R.P., see Manoharan, R. (103) 181

Reeves, B.E.A., see Pacy, P.J.H. (103) 231

Ritskes-Hoitinga, J., see de Deckere, E.A.M. (103) 291

Roach, P.D., Hosking, J., Clifton, P.M., Bais, R., Kusenic, B., Coyle, P., Wight, M.B., Thomas, D.W. and Nestel, P.J.  
 The effects of hypercholesterolemia, simvastatin and dietary fat on the low density lipoprotein receptor of unstimulated mononuclear cells (103) 245

Sako, Y., see Araki, A. (103) 149  
 Salomaa, V., Rasi, V., Pekkanen, J., Jauhainen, M., Vahtera, E., Pietinen, P., Korhonen, H., Kuulasmaa, K. and Ehnholm, C.

The effects of saturated fat and n-6 polyunsaturated fat on postprandial lipemia and hemostatic activity (103) 1

Salvatierra-Izaba, B., see Lerman-Garber, I. (103) 195

Sarbia, M., see Braun, M. (103) 93

Schmidt, E.B., Kristensen, S.D., De Caterina, R. and Illingworth, D.R.

The effects of n-3 fatty acids on plasma lipids and lipoproteins and other cardiovascular risk factors in patients with hyperlipidemia (103) 107

Schrör, K., see Braun, M. (103) 93

Sepúlveda-Amor, J.A., see Lerman-Garber, I. (103) 195

Smith, E.B., see Stirk, C.M. (103) 159

Soutar, A.K., see Feher, M.D. (103) 171

Stalenhoef, A.F.H., see Kroon, A.A. (103) 221

Stender, M., see Hense, H.W. (103) 21

Stirk, C.M., Kochhar, A., Smith, E.B. and Thompson, W.D.

Presence of growth-stimulating fibrin degradation products containing fragment E in human atherosclerotic plaques (103) 159

Stucchi, A.F., Vespa, D.B., Terpstra, A.H.M. and Nicolosi, R.J.

Effects of doxazosin, an  $\alpha_1$ -adrenergic inhibitor, on plasma lipid and lipoprotein levels, low density lipoprotein metabolism and cholesterol absorption in cynomolgus monkeys (103) 255

Sullivan, D.R., Lam, C.W.K., Jessup, W., Dean, R.T. and Hensley, W.J.

Postprandial changes in a apolipoprotein(a) concentration of triglyceride-rich lipoproteins can be reproduced by in vitro incubation: implications for underlying mechanism (103) 139

Swiatkowska, M., see Pawlowska, Z. (103) 13

Tapia-Conyer, R., see Lerman-Garber, I. (103) 195

Terpstra, A.H.M., see Stucchi, A.F. (103) 255

Thomas, D.W., see Roach, P.D. (103) 245

Thompson, W.D., see Stirk, C.M. (103) 159

Vahtera, E., see Salomaa, V. (103) 1

Valentino, B., see Campisi, D. (103) 267

Valle, M.S., see Mattila, K.J. (103) 205

Valtonen, V.V., see Mattila, K.J. (103) 205

van der Wal, A.C., Becker, A.E. and Das, P.K.

Medial thinning and atherosclerosis — evidence for involvement of a local inflammatory effect (103) 55

van Gilst, W.H., see Kroon, A.A. (103) 221

van Nielen, W.G.L., see de Deckere, E.A.M. (103) 291

Venkatesan, S., see Pacy, P.J.H. (103) 231

Vespa, D.B., see Stucchi, A.F. (103) 255

Watts, G.F., see Pacy, P.J.H. (103) 231

Webb, J.C., see Feher, M.D. (103) 171

Weber, A.-A., see Braun, M. (103) 93


Wight, M.B., see Roach, P.D. (103) 245

Wu, R., see Frostegård, J. (103) 213

Zamora-González, J., see Lerman-Garber, I. (103) 195

Zuckerman, S.H., Evans, G.F. and O'Neal, L.

Exogenous glucocorticoids increase macrophage secretion of apo E by cholesterol independent pathways (103) 43



## Subject Index (Vol. 103)

$\alpha_1$ -Adrenergic inhibitor, (103) 255  
Active PAI-1 antigen, (103) 131  
Acute phase reactant, (103) 65  
Adhesion, (103) 213  
Angiogenesis, (103) 159  
Antioxidants, (103) 73  
 $\alpha_1$ -Antitrypsin, (103) 123  
Apolipoprotein, (103) 65, 123  
Apolipoprotein(a), (103) 139  
Apolipoprotein B, (103) 255  
Apolipoprotein B-100, (103) 231  
Apolipoprotein E, (103) 43  
Apolipoprotein kinetics, (103) 231  
Arteriosclerosis, (103) 149  
Ascorbic acid, (103) 73  
Atherosclerosis, (103) 1, 29, 55, 139, 159, 181, 205, 213, 221  
Blood pressure, (103) 123  
Coronary, (103) 205  
Calcium apatite, (103) 181  
Cardiovascular risk, (103) 107  
Cardiovascular risk factors, (103) 81  
Chick chorioallantoic membrane, (103) 159  
Children, (103) 195  
Cholesterol, (103) 181, 195, 291  
Cholesterol ester, (103) 181  
Collagen, (103) 55  
Colloidal gold, (103) 245  
Cyclic AMP, (103) 43  
Defective apolipoprotein B, (103) 245  
Dexamethasone, (103) 43  
Diabetes mellitus, (103) 149  
Diet, (103) 81  
Doxazosin, (103) 255  
EDRF, (103) 73, 93  
Estrogen receptor, (103) 267  
Endothelial barrier function, (103) 279  
Endothelial cells, (103) 213  
Endothelial function, (103) 93  
Endothelium-dependent relaxation, (103) 221  
Exercise, (103) 81  
Factor VII, (103) 131  
Familial hypercholesterolaemia, (103) 245  
Fatty oils, (103) 107  
Fibrin degradation products, (103) 159  
Fibrinogen, (103) 131, 159  
Fibrinogen receptors, (103) 13  
Fish oils, (103) 107  
Gene amplification, (103) 171  
Glycoprotein IIb/IIIa complex, (103) 13  
Growth factors, (103) 159  
HDL subfractions, (103) 29 HSP27, (103) 267  
Hamster, (103) 291  
Haptoglobin, (103) 123  
Hemostatic activity, (103) 1  
High density lipoprotein, (103) 255  
Homocysteine, (103) 149  
Human aorta, (103) 267  
Hypercholesterolemia, (103) 93, 195, 221, 255  
Hyperlipidaemia, (103) 13  
Hyperlipidemia in the elderly, (103) 131  
Infections, (103) 205  
IR microscopy, (103) 181  
Imbalance between coagulation and fibrinolysis, (103) 131  
Inflammation, (103) 55  
LCAT, (103) 29  
LDL receptor gene, (103) 171  
Ligand binding, (103) 245  
Linoleic acid, (103) 279  
Lipoprotein lipase, (103) 231  
Lipoprotein(a), (103) 65, 123  
Lipoproteins, (103) 107, 291  
Low density lipoprotein, (103) 73, 255  
Lymphocytes, (103) 55  
Mexico, (103) 195  
Macroangiopathy, (103) 149  
Macrophage, (103) 43, 55  
Medial thinning, (103) 55  
Methylcobalamin, (103) 149

Monoclonal antibodies, (103) 55  
Mutation, (103) 171  
Myocardial infarctin, (103) 21, 65  
  
Nested case-control study, (103) 21  
Neutrophils, (103) 93  
  
Orosomucoid, (103) 123  
Oxidized low density lipoprotein, (103) 213  
  
Particle size, (103) 29  
Platelets, (103) 93  
Polygenic hypercholesterolaemia, (103) 245  
Polymorphism, (103) 171  
Polyunsaturated fats, (103) 1  
Postprandial lipemia, (103) 1  
Postprandial lipoprotein metabolism, (103) 139  
Pravastatin, (103) 221  
Prevention, (103) 81  
Probucol, (103) 73  
Prostacyclin, (103) 93  
Protein, (103) 181  
Proteoglycans, (103) 279  
  
Randomized study, (103) 81  
  
Saturated fats, (103) 1  
Sialic acid, (103) 123  
Silver enhancement, (103) 245  
Spectrophotometric assay, (103) 245  
Spectroscopy, (103) 181  
Stable isotope, (103) 231  
  
TRL apo(a), (103) 139  
Thrombosis, (103) 1  
TPA-PAI-1 complex, (103) 131  
Triglyceride-rich lipoproteins, (103) 139, 231  
  
Ultracentrifugation, (103) 29  
  
Very low density lipoprotein, (103) 231  
Vitamin E, (103) 21  
  
WHHL rabbits, (103) 221  
  
 $\beta$ -D-Xyloside, (103) 279

